School Inner City Air Study

NCT ID: NCT05953233

Last Updated: 2025-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-15

Study Completion Date

2030-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized clinical trial is to test the efficacy of high efficiency particulate air (HEPA) cleaners in reducing respiratory viral exposure and infections in elementary school classrooms. Classrooms will be randomized to active vs. sham HEPA cleaners. The main questions it aims to answer are:

* Do classroom HEPA cleaners reduce exposure to viruses?
* Do classroom HEPA cleaners reduce student and teacher infections?
* Do classroom HEPA cleaners reduce infections in family members?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Classrooms from participating schools will be randomized to active vs. sham HEPA cleaners. From enrolled classrooms, we will enroll students, teachers, and members of the household. We will collect the following:

* longitudinal classroom air samples
* longitudinal upper respiratory samples
* longitudinal symptom surveys using the Wisconsin Upper Respiratory Symptom Survey (WURSS) Viral testing on collected air and respiratory samples will be performed using digital polymerase chain reaction (dPCR).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Classrooms will be randomized in a 1:1 ratio using a random number generator to active vs sham HEPA arms
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
Sham cleaners are constructed by removing the filters from air cleaners and adding a sound generator rendering them indistinguishable from active HEPA cleaners.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active HEPA cleaner

Active HEPA cleaners will be placed in classrooms throughout the school year

Group Type EXPERIMENTAL

Active classroom HEPA cleaner

Intervention Type OTHER

Commercially available portable HEPA cleaner

Sham HEPA cleaner

Sham HEPA cleaners will be placed in classrooms throughout the school year

Group Type PLACEBO_COMPARATOR

Sham classroom HEPA cleaner

Intervention Type OTHER

Commercially available portable HEPA cleaner with filtration device removed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active classroom HEPA cleaner

Commercially available portable HEPA cleaner

Intervention Type OTHER

Sham classroom HEPA cleaner

Commercially available portable HEPA cleaner with filtration device removed

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children

* Grades K-5 (age 6-12 years)
* Attend one of the schools that the study team has permission to obtain classroom/school environmental samples
* Have no plans to move schools within the upcoming 12 months
* Subject and/or parent guardian must be able to understand and provide informed consent and also willing to participate in the study

Adults

* Adult (age 21 or older) parent, caretaker, or household member of child participating in this study, or teacher in classroom participating in study
* Able to understand and provide informed consent

Exclusion Criteria

Children

* Contraindication to or inability to participate in home self-collection of nasal swab samples
* Severe chronic diseases (e.g. cancer, genetic or congenital disorders interfering with mobility)
* Severe neurobehavioral, neurodevelopmental or psychiatric disorders requiring special assistance
* Families who do not speak English or Spanish well enough to complete the survey questions, as validated versions in other languages are not available for all of the measures

Adults

* Contraindication to or inability to participate in home self-collection of nasal swab samples
* Severe chronic diseases (e.g. cancer, genetic or congenital disorders interfering with mobility)
* Severe neurobehavioral, neurodevelopmental or psychiatric disorders requiring special assistance
* Families who do not speak English or Spanish well enough to complete the survey questions, as validated versions in other languages are not available for all of the measures
Minimum Eligible Age

6 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Children's Hospital

OTHER

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peggy S Lai

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mass General Brigham

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peggy Lai, MD MPH

Role: CONTACT

617-875-9878

Wanda Phipatanakul, MD MS

Role: CONTACT

857-218-5336

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Peggy Lai, MD MPH

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21AI178155

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB-P00045373

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Boston Puerto Rican Health Study
NCT03187704 COMPLETED NA
Home Air Purification for Eosinophilic COPD
NCT04252235 ACTIVE_NOT_RECRUITING NA